| Literature DB >> 32234776 |
Michael J Salazar1, Henrique Machado1, Nicholas A Dillon2, Hannah Tsunemoto3, Richard Szubin1, Samira Dahesh2, Joseph Pogliano2,4, George Sakoulas2, Bernhard O Palsson1,2,5, Victor Nizet2,5, Adam M Feist6,7.
Abstract
Antimicrobial susceptibility testing standards driving clinical decision-making have centered around the use of cation-adjusted Mueller-Hinton broth (CA-MHB) as the medium with the notion of supporting bacterial growth, without consideration of recapitulating the in vivo environment. However, it is increasingly recognized that various medium conditions have tremendous influence on antimicrobial activity, which in turn may have major implications on the ability of in vitro susceptibility assays to predict antibiotic activity in vivo. To elucidate differential growth optimization and antibiotic resistance mechanisms, adaptive laboratory evolution was performed in the presence or absence of the antibiotic nafcillin with methicillin-resistant Staphylococcus aureus (MRSA) TCH1516 in either (i) CA-MHB, a traditional bacteriological nutritionally rich medium, or (ii) Roswell Park Memorial Institute (RPMI), a medium more reflective of the in vivo host environment. Medium adaptation analysis showed an increase in growth rate in RPMI, but not CA-MHB, with mutations in apt, adenine phosphoribosyltransferase, and the manganese transporter subunit, mntA, occurring reproducibly in parallel replicate evolutions. The medium-adapted strains showed no virulence attenuation. Continuous exposure of medium-adapted strains to increasing concentrations of nafcillin led to medium-specific evolutionary strategies. Key reproducibly occurring mutations were specific for nafcillin adaptation in each medium type and did not confer resistance in the other medium environment. Only the vraRST operon, a regulator of membrane- and cell wall-related genes, showed mutations in both CA-MHB- and RPMI-evolved strains. Collectively, these results demonstrate the medium-specific genetic adaptive responses of MRSA and establish adaptive laboratory evolution as a platform to study clinically relevant resistance mechanisms.IMPORTANCE The ability of pathogens such as Staphylococcus aureus to evolve resistance to antibiotics used in the treatment of infections has been an important concern in the last decades. Resistant acquisition usually translates into treatment failure and puts patients at risk of unfavorable outcomes. Furthermore, the laboratory testing of antibiotic resistance does not account for the different environment the bacteria experiences within the human body, leading to results that do not translate into the clinic. In this study, we forced methicillin-resistant S. aureus to develop nafcillin resistance in two different environments, a laboratory environment and a physiologically more relevant environment. This allowed us to identify genetic changes that led to nafcillin resistance under both conditions. We concluded that not only does the environment dictate the evolutionary strategy of S. aureus to nafcillin but also that the evolutionary strategy is specific to that given environment.Entities:
Keywords: Staphylococcus aureuszzm321990; USA300; adaptive laboratory evolution; antibiotic resistance; drug resistance mechanisms; nafcillin
Year: 2020 PMID: 32234776 PMCID: PMC7112963 DOI: 10.1128/mSystems.00828-19
Source DB: PubMed Journal: mSystems ISSN: 2379-5077 Impact factor: 6.496
FIG 1Medium adaptation of S. aureus TCH1516. (A) Fitness trajectories depicting growth rate increase throughout the course of the medium adaptation ALE in RPMI+. Strains STR 1, 4, and 5 served as progenitors for the medium-adapted starting points in the tolerance evolution. (B) Clonal growth rates for single clones isolated by streaking endpoint populations. Measurements were determined from biological duplicates and an average of two consecutive flasks. STR strains are S. aureus RPMI+-adapted strains. STM strains are S. aureus CA-MHB-adapted strains. Values that are significantly different (P < 0.0001) from the value for the wild type (WT) by two-way ANOVA are indicated by a bar and asterisk. (C) ALE-derived strains maintain parental lineage virulence in a murine pneumonia model of infection. Values that are significantly different (P < 0.05) by t test with Welch’s correction are indicated by a bar and asterisk.
Key reproducibly occurring mutations detected in the final populations and clones of S. aureus TCH1516 after adaptive laboratory evolution in RPMI+
| Gene | Specific function | Mutation type | Protein and nucleotide | Strain(s) |
|---|---|---|---|---|
| Adenine phosphoribosyl transferase | SNP | D119E (GAT→GAA) | 8 | |
| SNP | H104Y (CAC→TAC) | 1 | ||
| SNP | P76S (CCT→TCT) | 6p | ||
| SNP | G73D (GGC→GAC) | 4 | ||
| SNP | A67V (GCT→GTT) | 2p, 6, 7 | ||
| SNP | A67T (GCT→ACT) | 5 | ||
| SNP | V66L (GTA→CTA) | 1p | ||
| SNP | V41L (GTA→TTA) | 2 | ||
| Manganese ABC transporter | SNP | L11I (TTA→ATA) | 4 | |
| SNP | L2I (TTA→ATA) | 2p | ||
| SNP | M1M (TTG→ATG)† | 3, 5, 6p, 7 | ||
| Manganese ABC transporter/Mn-dependent transcriptional regulator MntR | SNP | A→G, intergenic (−1/−121) | 4 | |
| SNP | C→T, intergenic (−2/−120) | 2p | ||
| INS | (GTTTAGGCTAACCTAATTAA)1→2, intergenic (−43/−79) | 3, 5, 6p, 7 | ||
| Serine/threonine-protein kinase | SNP | A124P (GCG→CCG) | 4 | |
| SNP | V470D (GTT→GAT) | 1 | ||
| Cold shock protein CspA | SNP | A60V (GCT→GTT) | 2 | |
| DEL | Δ1 bp, coding (34/201 nt) | 4 | ||
| Bacterial dynamin-like protein | SNP | Q1098E (CAA→GAA) | 2 | |
| SNP | S618T (TCT→ACT) | 6 | ||
| Single-stranded-DNA-specific exonuclease RecJ | SNP | S757S (TCG→TCT) | 3 | |
| SNP | A348V (GCA→GTA) | 8 | ||
| Lysostaphin resistance protein A | SNP | L48L (CTA→CTT) | 1 | |
| DEL | Δ1 bp, coding (1210/1260 nt) | 5 | ||
| SUB | 2 bp→AT, coding (1216 − 1217/1260 nt) | 5 | ||
The gene locus tag corresponds to USA300HOU_RSXXXXX. The gene nomenclature provided by prokka annotation, reflected in the mutation analysis, is shown in the parentheses.
SNP, single nucleotide polymorphism; INS, insertion; DEL, deletion; SUB, substitution.
nt, nucleotide; †, mutation led to formation of a start codon.
p denotes population.
Tolerance phenotypes for S. aureus USA300_TCH1516 and medium-adapted evolved populations on CA-MHB and RPMI+
| Ancestor strain | ALE no. | Initial | Starting | Final | Final | No. of flasks | CCD × 1012 |
|---|---|---|---|---|---|---|---|
| RPMI+ TALE | |||||||
| STR 1 | 7 | 1.17 ± 0.02 | 0.013 | 0.83 ± 0.12 | 65.52 | 184 | 15.2 |
| 9 | 1.20 ± 0.03 | 0.013 | 0.83 ± 0.08 | 50.4 | 174 | 13.4 | |
| STR 4 | 13 | 1.23 ± 0.08 | 0.013 | 0.85 ± 0.09 | 83.16 | 191 | 14.5 |
| 15 | 1.17 ± 0.08 | 0.013 | 0.83 ± 0.06 | 57.96 | 177 | 14.2 | |
| 17 | 1.04 ± 0.07 | 0.013 | 0.74 ± 0.11 | 65.52 | 172 | 13.6 | |
| STR 5 | 19 | 1.11 ± 0.1 | 0.013 | 0.87 ± 0.14 | 52.92 | 166 | 12.8 |
| 21* | 1.19 ± 0.04 | 0.013 | 0.99 ± 0.08 | 4.32 | 117 | 8.5 | |
| 23 | 1.22 ± 0.08 | 0.013 | 0.89 ± 0.14 | 57.96 | 171 | 13.6 | |
| CA-MHB TALE | |||||||
| STM 1 | 7 | 0.79 ± 0.07 | 0.5 | 0.77 ± 0.17 | 61.2 | 72 | 3.94 |
| 11 | 0.90 ± 0.12 | 0.5 | 0.87 ± 0.07 | 80.33 | 75 | 4.08 | |
| STM 2 | 13 | 0.94 ± 0.11 | 0.5 | 0.70 ± 0.03 | 61.2 | 68 | 3.75 |
| 15 | 0.87 ± 0.14 | 0.5 | 0.76 ± 0.13 | 61.2 | 70 | 3.81 | |
| STM 3 | 19 | 0.97 ± 0.16 | 0.5 | 0.88 ± 0.08 | 61.2 | 74 | 3.95 |
| 23 | 0.93 ± 0.11 | 0.5 | 0.93 ± 0.06 | 61.2 | 74 | 4.16 | |
Population growth rates for independent replicates were calculated by averaging the initial and final three flasks of the medium adaptation ALEs. An asterisk indicates premature end to experiment due to technical errors.
FIG 2Nafcillin adaptation of medium-adapted strains derived from S. aureus TCH1516. (A) Fitness trajectory for a typical TALE experiment, showing population growth rate and continuously increasing antibiotic concentration. The selected trajectory depicts SNFR9 exposed to nafcillin in RPMI+. (B) A plot of the MICs for selected clones from endpoint populations after nafcillin tolerization. The MICs for the wild-type TCH1516 (black squares) and TALE strains (green circles) on the respective medium are shown.
FIG 3Phenotypic characterization of TALE strains. (A) Growth rates of wild-type, medium-adapted, and nafcillin-adapted strains. The graph shows the measured growth rates of several selected endpoint clones for strains derived from either RPMI+ (STR and SNFR) or CA-MHB (STM and SNFM) evolutionary conditions. White bars represent clonal growth rates in CA-MHB, and gray bars represent the growth rate for the same clones in RPMI+. The graph shows the growth rates of three tolerization endpoint clones from both medium conditions along a lineage. Data presented are averages from triplicates. A comprehensive ANOVA statistical analysis is provided in Table S5 in the supplemental material. (B) Heat map of the nafcillin MIC fold change of TALE strains compared to the wild-type MIC in both medium types. STM, S. aureus CA-MHB-adapted strain; STR, S. aureus RPMI+-adapted strain; SNFM, S. aureus nafcillin-adapted strain in CA-MHB; SNFR, S. aureus nafcillin-adapted strain in RPMI+.
Key mutations for final endpoint clones of S. aureus TCH1516 after tolerance adaptive laboratory evolution in CA-MHB to nafcillin (SNFM)
| Gene | Specific function | Mutation | Protein and nucleotide | Strain |
|---|---|---|---|---|
| Adenine | SNP | G59D (GGC→GAC) | 11 | |
| SNP | I127N (ATT→AAT) | 19 | ||
| SNP | K82E (AAA→GAA) | 13 | ||
| Xanthine/guanine | SNP | Q6* (CAG→TAG) | 7 | |
| SNP | A84E (GCA→GAA) | 23 | ||
| Two-component sensor | SNP | G330D (GGT→GAT) | 11 | |
| SNP | T331I (ACA→ATA) | 19 | ||
| Transporter associated | SNP | T8K (ACG→AAG) | 13 | |
| SNP | V199A (GTT→GCT) | 23 | ||
| SNP | P126S (CCA→TCA) | 19 | ||
| Monofunctional | DEL | (T)7→6, coding (109/810 nt) | 11 | |
| SNP | Q215* (CAA→TAA) | 15 | ||
| SNP | S121* (TCA→TAA) | 13 | ||
The gene nomenclature provided by prokka annotation, reflected in the mutation analysis, is shown in the parentheses.
An asterisk indicates that a mutation led to a stop codon being formed.
Key mutations for final endpoint clones of S. aureus TCH1516 after tolerance adaptive laboratory evolution in RPMI+ to nafcillin (SNFR)
| Gene | Specific function | Mutation | Protein and nucleotide | Strain(s) |
|---|---|---|---|---|
| Beta-lactam-inducible | SNP | D586Y (GAT→TAT) | 7, 9, 13, 15, | |
| SNP | V488F (GTT→TTT) | 19 | ||
| DNA-directed RNA | SNP | A187T (GCA→ACA) | 13 | |
| SNP | A194V (GCA→GTA) | 19 | ||
| Cyclic di-AMP | SNP | N182K (AAC→AAG) | 9 | |
| SNP | S222F (TCC→TTC) | 23 | ||
| Putative transcriptional | DEL | Coding (235/1218 nt) | 7 | |
| SNP | Y121* (TAC→TAG) | 15 | ||
| SNP | D214N (GAC→AAC) | 19 | ||
| CodY family transcriptional | SNP | S204L (TCA | 9 | |
| SNP | K205N (AAA→AAT) | 15 | ||
| Cyclic di-AMP synthase | SNP | W76C (TGG→TGC) | 7 | |
| SNP | Q55H (CAG→CAT) | 13 | ||
| SNP | A80S (GCT→TCT) | 17 | ||
| Staphylococcal secretory | SNP | W70* (TGG→TAG) | 9 | |
| SNP | C45Y (TGT→TAT) | 15 | ||
| SNP | G65V (GGC→GTC) | 17 | ||
| SNP | G451S (GGT→AGT) | 7 | ||
| DEL | Coding (1239-1250/1812 nt) | 9 | ||
| DEL | Coding (29/1812 nt) | 13 | ||
| DEL | Coding (1327/1812 nt) | 15 | ||
| SNP | E341* (GAA→TAA) | 19 | ||
| Sensor histidine kinase | SNP | G92V (GGC→GTC) | 7 | |
| SNP | V66L (GTA→CTA) | 17, 19, 23 | ||
| Heme uptake protein MmpL11 | DEL | Coding (2065-2067/2280 nt) | 7, 19 | |
The gene nomenclature provided by prokka annotation, reflected in the mutation analysis, is shown in the parentheses. The gene locus tag corresponds to USA300HOU_RSXXXXX.
An asterisk indicates that a mutation led to a stop codon being formed.